I. Mikoshiba

发表

First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus

J. Polli, D. Nunez, R. Dobbins, 2013, BMC Pharmacology and Toxicology.

Silodosin (Urief®, Rapaflo®, Thrupas®, Urorec®, Silodix™): A Selective α1A Adrenoceptor Antagonist for the Treatment of Benign Prostatic Hyperplasia

J. Kudoh, I. Mikoshiba, Masaki Yoshida, 2012 .

Pharmacologic profiles of KRH-594, a novel nonpeptide angiotensin II-receptor antagonist.

M. Okuhira, I. Mikoshiba, H. Amano, 1997, Journal of cardiovascular pharmacology.

Tranilast suppresses vascular chymase expression and neointima formation in balloon-injured dog carotid artery.

S. Takai, M. Miyazaki, N. Shiota, 1999, Circulation.

Salivary Flow Rates and Pharmacokinetics in Healthy Japanese and Caucasian Volunteers Administered Oral Pilocarpine

S. Gallagher, R. Wasnich, I. Mikoshiba, 2003 .

Salivary Flow Rates andPharmacokinetics in Healthy Japaneseand Caucasian VolunteersAdministered Oral Pilocarpine : A Comparative Study.

S. Gallagher, R. Wasnich, I. Mikoshiba, 2003, Clinical drug investigation.

Rationale and evidence for the use of oxcarbazepine in neuropathic pain.

E. Carrazana, I. Mikoshiba, 2003, Journal of pain and symptom management.

First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus

J. Polli, D. Nunez, R. Dobbins, 2013, BMC Pharmacology and Toxicology.

In vitro pharmacological properties of KRH-594, a novel angiotensin II type 1 receptor antagonist.

M. Okuhira, I. Mikoshiba, K. Tamura, 1997, Biological & pharmaceutical bulletin.

Remogliflozin etabonate, a selective inhibitor of the sodium‐dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients

C. Kapitza, G. Golor, R. Dobbins, 2012, Diabetes, obesity & metabolism.